Quest Diagnostics Service Provider
Quest Diagnostics Incorporated is the world’s leading provider of diagnostic testing, information and services that patients and doctors need to make better healthcare decisions. Quest Diagnostics offers the most extensive clinical testing network in the United States, Mexico, the UK and India. Key Facts: 900 MDs and PhDs available for consultation at six esoteric testing laboratories. The world leading provider of specia…
The supplier does not provide quotations for this product through SelectScience. You can search for similar products in our Product Directory.
Quest Diagnostics Incorporated is the world’s leading provider of diagnostic testing, information and services that patients and doctors need to make better healthcare decisions.
Quest Diagnostics offers the most extensive clinical testing network in the United States, Mexico, the UK and India.
Key Facts:
- 900 MDs and PhDs available for consultation at six esoteric testing laboratories.
- The world leading provider of speciality testing, including gene-based and esoteric testing as well as routine to highly specialised testing.
- Broad test menu from routine to highly specialised testing.
- A service provider to the NHS and the Private sector in the United Kingdom, and a leading service provider of esoteric and gene-based testing in the United States.
Quest Diagnostics offers an extensive test menu with services covering:
- Haematology
- Biochemistry
- Endocrinology
- Histology
- Cytology
- Immunology
- Microbiology
- Molecular Biology
- Sexual Health Screening
Follow the product technical page link for access to the full test menu provided by Quest Diagnostics.
Quest Diagnostics to introduce Ki-67 IHC MIB-1 pharmDx, the first companion diagnostic for Verzenio
As the first laboratory to validate Ki-67 IHC MIB-1 pharmDx Quest plans to make testing available nationally by the end of October 2021
Quest Diagnostics marks 10 years as CEO Cancer Gold Standard employer
Gold Standard accreditation signifies commitment to reducing employee cancer risk
FDA authorizes Quest Diagnostics COVID-19 nasal specimen self-collection kit for emergency use
Company to make the device available through broad range of healthcare, state, employer and consumer-initiated channels
Quest Diagnostics acquires Blueprint Genetics to broaden access to actionable insights for genetic and rare diseases
Acquisition adds platform in gene variant interpretation based on next generation sequencing
Quest Diagnostics and Inovalon Bring Real-Time, Point-of-Care Analytics to HIMSS16 with Data Diagnostics™
Integrated with nearly 600 EHR platforms to align clinical management with quality, utilization and financial performance goals
